NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), an Israel-based company developing treatments for severe neurodegenerative diseases, announced on Tuesday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to enrol patients in the United States for its phase 2b PARADIGM study of its lead drug candidate PrimeC to treat amyotrophic lateral sclerosis (ALS).
The company is currently enrolling patients in Israel and is likely to open clinical sites for patient recruitment in the European Union in the coming weeks. The company has received Orphan Drug Designation with the FDA and the European Medicines Agency (EMA).
The study is intended to synergistically target various key ALS mechanisms that contribute to motor neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation to potentially inhibit the progression of ALS. It is a Phase 2b double-blind, placebo-controlled, multinational clinical trial that intends to evaluate the efficacy, safety and tolerability, in people living with ALS. It is enrolling and randomising 69 people living with ALS in a 2:1 ratio to receive PrimeC or placebo, respectively. Participants who complete the six-month double-blind, placebo-controlled dosing period will be converted to the PrimeC active arm for a 12-month open label extension.
NeuroSense expects to enrol and dose the first US patients in the next few weeks at leading ALS centres on both the east and west coast.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT